AXSM Jul 2024 65.000 put
| Previous Close | 1.5500 |
| Open | 1.5500 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 65.00 |
| Expire Date | 2024-07-19 |
| Day's Range | 1.5500 - 1.5500 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 54 |
GlobeNewswireAxsome Therapeutics Supports Alzheimer’s & Brain Awareness Month
NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, announced today it is supporting Alzheimer’s & Brain Awareness Month this June, to help increase awareness and understanding of the challenges Alzheimer’s disease (AD) presents to patients, their caregivers, and their loved ones, and the importance of brain and mental health as cor
- GlobeNewswire
Axsome Therapeutics to Participate in Upcoming Investor Conferences
NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Axsome will participate in two upcoming investor conferences. The conference details are as follows: William Blair 44th Annual Growth Stock Conference, on Wednesday, June 5, at 2 p.m. Central Time. Herriot Tabuteau, MD, Axsome’s Chief Executive Officer, will pre
- GlobeNewswire
Axsome Therapeutics Highlights Data on Solriamfetol Demonstrating Improvement in Cognitive Function in Patients with Obstructive Sleep Apnea or Narcolepsy at SLEEP 2024
Data on solriamfetol featured in two oral plenary sessionsNEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced five presentations, including two featured oral plenary presentations, on solriamfetol at SLEEP 2024, the 38th annual meeting of the American Academy of Sleep Medicine (AASM) and the Sleep Research Society (SR
